Aethlon Medical, Inc

15 articles with Aethlon Medical, Inc

• Aethlon Medical to Present at Sequire Biotechnology Conference on February 2nd, 2023

  1/31/2023

  Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease,  announced today that it will be presenting virtually at the upcoming Sequire Biotechnology Conference on Thursday, February 2nd, at 10:00 AM ET.

• Aethlon Medical Announces Contract with NAMSA to Advance Hemopurifier Clinical Programs in Cancer

  1/30/2023

  Aethlon Medical, Inc. today announced that it has entered into an agreement with NAMSA.

• Aethlon Medical to Present at Two Investor Conferences in September 2022

  9/6/2022

  Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, announced that it will be presenting at two investor conferences in September.

• Aethlon Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update

  8/9/2022

  Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, reported financial results for its first quarter ended June 30, 2022 and provided an update on recent developments.

• Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 9, 2022

  8/3/2022

  Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its first quarter ended June 30, 2022, at 4:15 p.m. EST on Tuesday, August 9, 2022.

• Aethlon Medical Announces Publication of Peer-Reviewed Journal Article Describing Hemopurifier Resin Binding of Seven COVID-19 Variants

  7/28/2022

  Aethlon Medical, Inc., a medical therapeutic company focused on developing products to diagnose and treat cancer and life threatening infectious diseases, announced the publication of a peer-reviewed journal article in PLOS ONE.

• Aethlon Medical Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

  7/11/2022

  Aethlon Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an amendment to the protocol of its ongoing clinical trial investigating the Aethlon Hemopurifier® for patients with severe COVID-19.

• Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 28, 2022

  6/21/2022

  Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022 , at 4:15 p.m. EST on Tuesday , June 28, 2022.

• Aethlon Medical to Present at the H.C. Wainwright Global Investment Conference

  5/17/2022

  Aethlon Medical, Inc., announced that it will be presenting at the H.C. Wainwright Global Investment Conference.

• Aethlon Medical Publishes In Vitro Studies Demonstrating Hemopurifier Resin Binding of Seven Clinically Relevant COVID-19 Variants

  5/2/2022

  Aethlon Medical, Inc. (Nasdaq: AEMD), today announced the publication of a pre-print manuscript featuring data that demonstrated Aethlon's proprietary GNA affinity resin was able to bind seven clinically relevant SARS-CoV-2 variants in vitro, including the Delta and Omicron variants.

• Aethlon Medical, Inc. Appoints Angela Rossetti to Board of Directors

  3/28/2022

  Aethlon Medical, Inc., a medical technology company focused on developing products to diagnose and treat life and organ threatening diseases, announced the appointment of Angela Rossetti to the Aethlon Board of Directors, effective April 1, 2022.

• Aethlon Medical Announces Third Quarter 2021 Financial Results and Provides Corporate Update

  2/14/2022

  Aethlon Medical, Inc., a company developing medical technology to treat cancer and life-threatening infectious diseases, reported financial results for its third quarter ended December 31, 2021 and provided an update on recent developments.

• Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 14, 2022

  1/31/2022

  Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter fiscal year 2022, ended December 31, 2021, at 4:15 p.m. EST on Monday, February 14, 2022.

• Aethlon Medical Announces Second Quarter 2021 Financial Results and Provides Corporate Update

  11/9/2021

  Aethlon Medical, Inc., a company developing medical technology to treat cancer and life-threatening infectious diseases, reported financial results for its second quarter ended September 30, 2021 and provided an update on recent developments.

• Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 9, 2021

  11/2/2021

  Aethlon Medical, Inc., a company developing medical technology to treat cancer and life-threatening infectious disease, announced that it will issue financial results for its second quarter fiscal year 2022, ended September 30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.